Investment Landscape: Progressive Supranuclear Palsy covers the current R&D investment,
clinical trial pipeline, and funding trends for Progressive Supranuclear Palsy research.
Last updated: 2026-04-01 09:38 PT
Total Clinical Trials: 0
Active Trials (Recruiting/Active): 0
Progressive Supranuclear Palsy has 0 total clinical trials, representing a rare but devastating tauopathy. The distinctive tau pathology creates opportunities for targeted therapeutic development.
PSP research is benefiting from advances in tau PET imaging and fluid biomarkers. The pure tau pathology makes PSP an attractive indication for anti-tau therapies. Tau aggregation inhibitors and tau immunotherapy are primary focus areas for disease modification.
Only 0.0% of trials are in Phase 3, indicating a significant gap between early discovery and late-stage clinical development. Investment in clinical trial infrastructure and regulatory engagement could accelerate late-stage programs.
Based on trial count analysis, the following mechanism categories represent either well-invested areas or underserved opportunities:
Continued Phase 2/3 readouts expected for leading mechanisms. Focus on biomarker-positive trials for enrichment. Regulatory pathways becoming clearer for disease-modifying therapies.
Gene therapies and RNA-targeting modalities expected to expand. Combination therapy trials likely to increase. Patient stratification through genetic and biomarker testing becoming standard.
Prevention trials in pre-symptomatic populations. Personalized medicine approaches based on genetic profiles. Disease-modifying therapies potentially becoming standard of care.
Last updated: 2026-04-01